GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Pfizer

GSK's RSV vaccine candidate for adults aged 60 years or above achieves statistically significant and clinically meaningful efficacy in a phase III study. Regulatory submissions are likely in the second half of 2022.

GSK's RSV Vaccine Candidate Offers Robust Protection in Elderly

Sanofi

The shot provoked a stronger immune response against omicron than a booster dose of Pfizer's vaccine, Sanofi said.

Sanofi, GSK Covid Booster Triggers ‘Strong Immune Response' Against Multiple Variants Including Omicron

There are currently no RSV vaccines approved in the U.S. Approval for its RSV vaccine could mark a big win for GSK, formerly GlaxoSmithKline.

GSK Reports a Win for Its RSV Vaccine

Ergomed PLC (AIM:ERGO, ETR:2EM) said Anne Whitaker will join its board as an independent non-executive director after the pharmaceutical industry service provider's AGM on Friday. She has worked across the pharmaceutical, biotech and speciality pharma sectors for 30 years including in senior executives roles at Sanofi, GlaxoSmithKline and Synta Pharmaceuticals.

Ergomed appoints former GSK and Sanofi executive to board

GlaxoSmithKline PLC (LSE:GSK) said it engaged regulators to submit a new respiratory virus vaccine for approval before the end of the year.   The pharma group announced interim results of the third phase of the AReSVi 006 trial of its respiratory syncytial virus vaccine today, a virus which can exacerbate pulmonary disease, asthma and heart failure.

GSK seeks approval for respiratory vaccine after trials show 'meaningful efficacy'

AstraZeneca

Novartis

Vaxart

It depends on which subsector you're talking about.

What Could a Recession Mean for Healthcare Stocks?

Regeneron Pharmaceuticals

Could these biotech stocks be worth keeping an eye on in the stock market today?

What Stocks To Buy Today? 3 Biotech Stocks To Know

GlaxoSmithKline, which was recently renamed GSK PLC ( LSE:GSK , Financial) ( GSK , Financial), is a mash up of the old GlaxoWellcome and SmithKline Beecham businesses. This combination will be undone when the consumer health care (SmithKline) and pharmaceuticals (Glaxo) businesses formally demerge next month.

GSK Restructuring Provides Opportunity for Re-Rating

The FDA approves GSK's Priorix vaccine for active immunization for the prevention of measles, mumps and rubella in individuals aged 12 months and older.

GSK Gets FDA Nod for Measles, Mumps & Rubella Vaccine, Priorix

PHILADELPHIA--(BUSINESS WIRE)-- #GSK--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older. PRIORIX is currently licenced in more than 100 countries worldwide, including all European countries, Canada, Australia and New Zealand, with more than 800 million doses distributed to date. “We'

GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older

GlaxoSmithKline PLC (LSE:GSK) said its Priorix vaccine has been approved by the US Food and Drug Administration (FDA) for active immunisation for the prevention of measles, mumps and rubella (MMR) in people 12 months and older.  The approval means US patients now have an additional source of MMR vaccine, the pharma group said in a statement.

GSK's Priorix MMR vaccine gets US FDA approval

British drugmaker GSK said on Monday its vaccine, Priorix, was approved by the U.S. Food and DrugAdministration (FDA) for the prevention of measles, mumps and rubella for those aged one year and above.

GSK's measles prevention vaccine gets U.S. approval

At a £50 billion IPO, Haleon could trade at a Market Cap/EBIT of 19x if we annualized GSK's Q1 results. Haleon is expected to grow net sales between 4-6% according to management.

Why I'll Likely Sell Haleon Shares After GSK Demerger

After Over 10 Years of Fighting the 'Food' Fight, America's #1 Heartburn Brand*  is Now Empowering Fans to Flaunt Their Love for Food WARREN, N.J. , June 2, 2022 /PRNewswire/ -- GlaxoSmithKline (LSE: GSK) (NYSE: GSK) – Go ahead and revel in that ramen, indulge on pizza and savor even the sauciest of wings without fear.

The Food Fight is Over: TUMS® Declares It is Time to Love Food Back

GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.

GSK Receives Regulatory Nod for Consumer Healthcare Demerger

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today provided an update on its ownership interest in Haleon plc (Haleon), the newly independent company which will hold the joint Consumer Healthcare business of GSK plc (NYSE: GSK) and Pfizer following the demerger of approximately 80% of GSK's ownership interest in the business to GSK's shareholders. Following the demerger and listing of Haleon on the London Stock Exchange (LSE), which is expected to occur in July 2022, Pfizer will continue

Pfizer Provides Update on Ownership Interest in Haleon

GSK, the U.K. drugmaker, has applied to Britain's regulator to list Haleon on the London Stock Exchange on July 18.

Pfizer to Exit GSK Consumer Health Venture After Spin-Off

Pfizer plans to exit its 32% stake in Haleon, its consumer health joint venture with GSK, after the business is spun off as an independent company in July, GSK said on Wednesday.

Pfizer to exit GSK's consumer health arm after spin-off

Shares in Haleon PLC, the consumer healthcare business being spun out by GlaxoSmithKline PLC and Pfizer Inc (NYSE:PFE), are expected to begin trading as an independent company on the London Stock Exchange in London on 18 July. The FTSE 100-listed pharma group said it has filed a prospectus for the submission of Haleon's ordinary shares to the stock market with the Financial Conduct Authority, which are currently awaiting approval.

GSK and Pfizer spin-out expected to list on LSE in July

GSK signs an agreement to acquire Affinivax, Inc. for a $2.1 billion upfront payment. The company is looking to boost its vaccine pipeline with this acquisition.

GSK to Boost Vaccine Portfolio With Affinivax Acquisition

The recent consumer healthcare interest signals that GSK is undervalued. Shareholders should benefit from the spin off as company should move towards fair value territory.

GSK: 4.5% Dividend Yield And Undervalued

GSK plc (LSE/NYSE: GSK) announced that it has entered into a definitive agreement to buy Affinivax. These are the details.

Why GSK (GSK) Is Buying Affinivax For Over $2 Billion

GSK PLC said Tuesday that it has agreed to buy clinical-stage biopharmaceutical company Affinivax, Inc. for up to $3.3 billion.

GSK to pay up to $3.3 billion for biopharma Affinivax

The U.K. drugmaker will make an upfront payment of $2.1 billion for Affinivax and up to $1.2 billion in potential development milestones.

GSK to Buy U.S. Biotech Affinivax in $3.3 Billion Deal

GlaxoSmithKline PLC (LSE:GSK) is to bolster its vaccine pipeline in a deal worth up to US$3.3bn. It is acquiring Affinivax Inc, which gives it access to a technology being developed to treat pneumococcal diseases such as pneumonia, meningitis and bloodstream infections.

News for GlaxoSmithKline Stock (GSK)